Medication-Related Osteonecrosis of the Jaw Associated with Pazopanib Monotherapy
Int. j. odontostomatol. (Print); 16 (1), 2022
ABSTRACT: Pazopanib, an antiangiogenic agent, has shown promising results in controlling tumor growth and metastasis in patients with renal cell carcinoma. The use of pazopanib in the management of malignancies has increased over recent years, with more patients at risk of developing medication-related o...